The CEO, General Counsel, 2 directors and a officer bought 56,600 shares or $1,043,291 worth of stock.

Recently, shares of Par Pharmaceutical Cos. plunged after the company told investors competitive pressures would hurt its 2007 earnings.

The stock trades for 11x cash flow.

The CEO, General Counsel, 2 directors and a officer bought 56,600 shares or $1,043,291 worth of stock.

Recently, shares of Par Pharmaceutical Cos. plunged after the company told investors competitive pressures would hurt its 2007 earnings.

The stock trades for 11x cash flow.

Par Pharmaceutical (PRX) traded down after a Friedman Billings Ramsey analyst downgraded shares on Monday, saying the generic drug maker will not recover from declining sales until 2009.
On Friday, Par gave an annual forecast that fell far short of analyst estimates, and the stock dropped 14.4 percent, reaching a year low. The company said sales have been weak due to difficult competition, which will lead to weaker revenue and less profit for the year.

Upgraded by Leerink Swann from Mkt Perform to Outperform

recommendation

seems like a good company and has much going for it. Though profits aren't up I think this company has some promise to it.

drugs